JP2025078629A5 - - Google Patents

Download PDF

Info

Publication number
JP2025078629A5
JP2025078629A5 JP2025012821A JP2025012821A JP2025078629A5 JP 2025078629 A5 JP2025078629 A5 JP 2025078629A5 JP 2025012821 A JP2025012821 A JP 2025012821A JP 2025012821 A JP2025012821 A JP 2025012821A JP 2025078629 A5 JP2025078629 A5 JP 2025078629A5
Authority
JP
Japan
Prior art keywords
antigen
seq
antibody
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2025012821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025078629A (ja
JP7899374B2 (ja
Filing date
Publication date
Priority claimed from EP19206959.9A external-priority patent/EP3816185A1/en
Application filed filed Critical
Publication of JP2025078629A publication Critical patent/JP2025078629A/ja
Publication of JP2025078629A5 publication Critical patent/JP2025078629A5/ja
Application granted granted Critical
Publication of JP7899374B2 publication Critical patent/JP7899374B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2025012821A 2019-11-04 2025-01-29 多重特異性抗体 Active JP7899374B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19206959.9A EP3816185A1 (en) 2019-11-04 2019-11-04 Multispecific antibody directed against pd-l1 and a tumor-associated antigen
EP19206959.9 2019-11-04
JP2022524675A JP2023501146A (ja) 2019-11-04 2020-11-04 多重特異性抗体
PCT/EP2020/080941 WO2021089609A1 (en) 2019-11-04 2020-11-04 Multispecific antibody

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022524675A Division JP2023501146A (ja) 2019-11-04 2020-11-04 多重特異性抗体

Publications (3)

Publication Number Publication Date
JP2025078629A JP2025078629A (ja) 2025-05-20
JP2025078629A5 true JP2025078629A5 (cg-RX-API-DMAC7.html) 2025-10-27
JP7899374B2 JP7899374B2 (ja) 2026-08-03

Family

ID=68426333

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022524675A Pending JP2023501146A (ja) 2019-11-04 2020-11-04 多重特異性抗体
JP2025012821A Active JP7899374B2 (ja) 2019-11-04 2025-01-29 多重特異性抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022524675A Pending JP2023501146A (ja) 2019-11-04 2020-11-04 多重特異性抗体

Country Status (9)

Country Link
US (1) US20220411536A1 (cg-RX-API-DMAC7.html)
EP (2) EP3816185A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023501146A (cg-RX-API-DMAC7.html)
KR (2) KR20260110258A (cg-RX-API-DMAC7.html)
CN (1) CN114981306A (cg-RX-API-DMAC7.html)
AU (1) AU2020379182A1 (cg-RX-API-DMAC7.html)
CA (1) CA3159904A1 (cg-RX-API-DMAC7.html)
IL (1) IL292727A (cg-RX-API-DMAC7.html)
WO (1) WO2021089609A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11319371B2 (en) * 2017-06-05 2022-05-03 Numab Therapeutics AG Anti-CD3 antibodies
WO2022136693A1 (en) 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2022242682A1 (en) * 2021-05-21 2022-11-24 Beigene, Ltd. Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
US20240352153A1 (en) * 2021-07-23 2024-10-24 Akeso Biopharma, Inc Pharmaceutical composition and use
CN117730103A (zh) * 2021-08-02 2024-03-19 盛禾(中国)生物制药有限公司 一种多特异性抗原结合蛋白及其应用
WO2023088295A1 (zh) * 2021-11-17 2023-05-25 江苏先声药业有限公司 一种多特异性抗体及其药物用途
MX2024008500A (es) * 2022-01-09 2024-08-26 I Mab Biopharma Co Ltd Construcciones multiespecíficas y usos de estas.
IL314169A (en) * 2022-01-26 2024-09-01 Zymeworks Bc Inc Trispecific immunomodulatory T cell engager proteins
WO2023141856A1 (zh) * 2022-01-27 2023-08-03 岩唐生物科技(杭州)有限责任公司 靶向cd3的多特异性抗体及其应用
EP4524248A4 (en) * 2022-05-12 2026-07-01 Astellas Pharma Inc MULTISPECIFIC ANTI-TAA AND ANTI-CD3 ANTIBODY
EP4540290A4 (en) * 2022-06-14 2026-07-01 Invenra Inc Multi-species liaison agents targeting B7H3 and GD2, and their uses
WO2024036207A2 (en) * 2022-08-11 2024-02-15 University Of Florida Research Foundation, Incorporated Rabbit monoclonal antibodies targeting multiple myeloma cell surface antigens
JP2025529310A (ja) * 2022-09-06 2025-09-04 ティージェイ バイオファーマ (シャンハイ) カンパニー, リミテッド 多特異性構築物およびその使用
WO2024061297A1 (en) * 2022-09-22 2024-03-28 Shanghai Henlius Biotech , Inc. Anti-b7h3 antibodies, multispecific antibodies and methods of use
WO2024197709A1 (zh) * 2023-03-30 2024-10-03 中国科学院深圳先进技术研究院 一种t细胞衔接器及其制备方法和应用
WO2025016012A1 (en) * 2023-07-14 2025-01-23 Genor Biopharma Co., Ltd. Anti-PD-1/CTLA-4/TIGIT TRISPECIFIC ANTIBODIES AND USE THEREOF
EP4754149A1 (en) * 2023-07-29 2026-06-10 Shanghai Kaijin Biotechnology , Ltd Modified type e multi-specific antibodies

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
US20040071705A1 (en) 2002-06-21 2004-04-15 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004042072A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
KR20060095385A (ko) 2005-02-28 2006-08-31 엘지전자 주식회사 세탁기의 헹굼 행정 제어 방법
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
WO2011006915A2 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
WO2016011069A1 (en) * 2014-07-15 2016-01-21 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of cd38 agonists (antibodies)
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
KR20250091329A (ko) 2015-06-15 2025-06-20 누맙 세러퓨틱스 아게 이종 이량체 다중 특이적 항체 포맷
IL304871A (en) 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
AU2017222700B2 (en) * 2016-02-26 2018-09-27 Imunexus Therapeutics Limited Multi-specific molecules
BR112018071612A2 (pt) 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
KR102379464B1 (ko) * 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
AR110348A1 (es) * 2016-12-07 2019-03-20 Agenus Inc Anticuerpos y métodos de su utilización
US12098203B2 (en) * 2017-06-05 2024-09-24 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
IL273578B2 (en) * 2017-10-10 2026-03-01 Numab Therapeutics AG Antibodies directed against PD-1 and methods of use thereof
EP3470426A1 (en) * 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
US12202911B2 (en) * 2017-10-10 2025-01-21 Numab Therapeutics AG Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
EP3470429A1 (en) * 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
WO2019166650A1 (en) * 2018-03-02 2019-09-06 Cdr-Life Ag Trispecific antigen binding proteins
CN109942704B (zh) * 2019-04-12 2023-01-20 深圳普瑞金生物药业股份有限公司 Hsa单域抗体、核酸及试剂盒
MX2022014768A (es) * 2020-05-29 2023-01-11 Numab Therapeutics AG Anticuerpo multiespecifico.
EP3988568A1 (en) * 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
AU2021405066A1 (en) * 2020-12-23 2023-06-22 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
JP7858665B2 (ja) * 2021-02-02 2026-05-14 ヌマブ セラピューティックス アーゲー Ror1およびcd3に対する特異性を有する多重特異性抗体

Similar Documents

Publication Publication Date Title
Hayden et al. Antibody engineering
IL295604A (en) Methods of making chimeric antigen receptor-expressing cells
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
JP2022548796A5 (cg-RX-API-DMAC7.html)
JP2022514693A5 (cg-RX-API-DMAC7.html)
JP2021518142A5 (cg-RX-API-DMAC7.html)
IL312224B1 (en) Guidance and navigation control proteins and method of making and using thereof
HRP20251135T1 (hr) Postupci dobivanja kimernih stanica koje eksprimiraju antigenske receptore
US20220396635A1 (en) Trivalent binding molecules
CN108610420A (zh) 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
CN106883297A (zh) 基于ch3结构域的异二聚体分子、其制备方法及用途
JP2024508672A5 (cg-RX-API-DMAC7.html)
CN114127111A (zh) 与nkp30结合的抗体分子及其用途
JP2025508316A5 (cg-RX-API-DMAC7.html)
CN104829727B (zh) 一种双特异性抗体cd19×cd3的构建及应用
JP2023525720A5 (cg-RX-API-DMAC7.html)
JP2024511423A5 (cg-RX-API-DMAC7.html)
JP2020522267A (ja) 少なくともcd3及びhsaを標的とするヘテロ二量体多重特異性抗体フォーマット
JP2020535796A5 (cg-RX-API-DMAC7.html)
US20230002488A1 (en) Guidance and navigation control proteins and method of making and using thereof
EP4139346A1 (en) Heterodimeric proteins
Loh et al. Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies
WO2022093694A1 (en) Polypeptides targeting hpv peptide-mhc complexes and methods of use thereof
EP4469478A1 (en) Bispecific molecule with tunable affinity to a targetted antigen
CN112940136B (zh) 一种嵌合抗原结合受体car、载体、car-t细胞、药物组合物及其应用